Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pitts

Showing results (191-200 of 268) with videos related to

Pageof 27
Sort By:
Neoplasia (New York, N.Y.)|November 3, 2009
HE3235 inhibits growth of castration-resistant prostate cancerTheodore D Koreckij, Richard J Trauger, Robert Bruce Montgomery, et al.
Frontiers in Oncology|April 17, 2025
Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancerAnna R Schreiber, Stephen G Smoots, Marilyn M Jackson, et al.
Journal of Visualized Experiments : Jove|January 2, 2023
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human TumorsJordi M Lanis, Matthew S Lewis, Hannah Strassburger, et al.
Endocrine-Related Cancer|July 21, 2019
Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACCAdwitiya Kar, Yu Zhang, Betelehem W Yacob, et al.
Journal of Visualized Experiments : Jove|October 22, 2016
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer TherapiesStacey Bagby, Wells A Messersmith, Todd M Pitts, et al.
Kidney International|February 8, 2025
Pathological findings of immunotherapy-induced nephrotoxicity in a humanized immune system mouse modelSarah C Asby, Lauren E Thompson, Michael Goedken, et al.
Immunology and Cell Biology|August 26, 2015
TLR3 drives IRF6-dependent IL-23p19 expression and p19/EBI3 heterodimer formation in keratinocytesDivya Ramnath, Kathryn Tunny, Daniel M Hohenhaus, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Journal of Molecular Biology|June 23, 2018
Biliverdin Reductase B Dynamics Are Coupled to Coenzyme BindingNatasia Paukovich, Mengjun Xue, James R Elder, et al.
Molecular Oncology|April 24, 2012
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancerJohn J Arcaroli, Rebecca W Powell, Marileila Varella-Garcia, et al.
Pageof 27

Showing results (191-200 of 268) with videos related to

Sort By:
Pageof 27
Neoplasia (New York, N.Y.)|November 3, 2009
HE3235 inhibits growth of castration-resistant prostate cancerTheodore D Koreckij, Richard J Trauger, Robert Bruce Montgomery, et al.
Frontiers in Oncology|April 17, 2025
Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancerAnna R Schreiber, Stephen G Smoots, Marilyn M Jackson, et al.
Journal of Visualized Experiments : Jove|January 2, 2023
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human TumorsJordi M Lanis, Matthew S Lewis, Hannah Strassburger, et al.
Endocrine-Related Cancer|July 21, 2019
Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACCAdwitiya Kar, Yu Zhang, Betelehem W Yacob, et al.
Journal of Visualized Experiments : Jove|October 22, 2016
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer TherapiesStacey Bagby, Wells A Messersmith, Todd M Pitts, et al.
Kidney International|February 8, 2025
Pathological findings of immunotherapy-induced nephrotoxicity in a humanized immune system mouse modelSarah C Asby, Lauren E Thompson, Michael Goedken, et al.
Immunology and Cell Biology|August 26, 2015
TLR3 drives IRF6-dependent IL-23p19 expression and p19/EBI3 heterodimer formation in keratinocytesDivya Ramnath, Kathryn Tunny, Daniel M Hohenhaus, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Journal of Molecular Biology|June 23, 2018
Biliverdin Reductase B Dynamics Are Coupled to Coenzyme BindingNatasia Paukovich, Mengjun Xue, James R Elder, et al.
Molecular Oncology|April 24, 2012
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancerJohn J Arcaroli, Rebecca W Powell, Marileila Varella-Garcia, et al.
Pageof 27